Loading page content…
Loading page content…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Tender notice |
| Buyer: | The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") |
| Main Category: | Goods |
| Procurement Method: | Open procedure |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | £59,145,973 |
This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland. The Goods have been separated into forty-one (41) categories, each of which is identified as a “Lot”. Full details of each Lot is contained in section II.2 of this Notice.
Document pack· 1 file
Published contracts in the last 12 months
3
total contracts
£53.0m
total value
£52,999,636
average contract size
Typical categories
Pipeline status
Not addedContract imported automatically · AI writes the response
Application Deadline
17 October 2022
Closed
Estimated Value
£59,145,973
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Release Date: |
| 16 September 2022 |
| Application Deadline: | 17 October 2022 |
| Procurement ID (OCID): | ocds-h6vhtk-0368ee |
| Notice Reference: | 025989-2022 |
All 2 notices for this procurement, oldest first.
Generic and Biosimilar Cancer Medicines
Earlier notices predate the Procurement Act 2023 (commenced 24 Feb 2025) and therefore don't carry UK1–UK17 codes.